Si-bone (SIBN) Q2 Revenue Jumps 22%

Si-bone (NASDAQ:SIBN), a medical device innovator focused on minimally invasive surgery for joint dysfunction and pelvic conditions, released its second quarter 2025 results on August 4, 2025. The company reported GAAP revenue of $48.6 million and a GAAP net loss per share of $(0.14) for Q2 2025. Both figures surpassed analyst forecasts of $48.12 million and $(0.18) GAAP, respectively. The period marked a solid quarter for Si-bone, with double-digit revenue growth, posted positive adjusted EBITDA, and raised its full year outlook. U.S. revenue drove results, while international sales remained flat. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Si-bone designs and sells implant systems and related instruments for spinal and pelvic surgeries. Its core focus is on the sacroiliac (SI) joint, a frequent cause of lower back pain, as well as pelvic trauma and complex spinal cases. The company’s products, including iFuse-3D (a 3D-printed titanium implant), iFuse TORQ (a screw-like implant for trauma fixation), and iFuse Bedrock Granite (used for pelvic anchoring in spinal fusion), are supported by clinical studies and aim to simplify surgery and improve patient outcomes.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool